Burzynski Research Financials
| BZYR Stock | USD 0.04 0.01 28.57% |
Burzynski |
Understanding current and past Burzynski Research Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Burzynski Research's financial statements are interrelated, with each one affecting the others. For example, an increase in Burzynski Research's assets may result in an increase in income on the income statement.
Burzynski Research Stock Summary
Burzynski Research competes with ProKidney Corp, Orchestra BioMed, Lixte Biotechnology, Scpharmaceuticals, and DiaMedica Therapeutics. Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to treat cancer. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas. Burzynski Research is traded on OTC Exchange in the United States.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US1231591058 |
| Business Address | 9432 Katy Freeway, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.burzynskiclinic.com |
| Phone | 713 335 5697 |
| Currency | USD - US Dollar |
Burzynski Research Key Financial Ratios
There are many critical financial ratios that Burzynski Research's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Burzynski Research reports annually and quarterly.| Return On Asset | -127.66 | |||
| Beta | 1.45 |
Burzynski Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Burzynski Research's current stock value. Our valuation model uses many indicators to compare Burzynski Research value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Burzynski Research competition to find correlations between indicators driving Burzynski Research's intrinsic value. More Info.Burzynski Research is rated below average in return on asset category among its peers. It is rated below average in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Burzynski Research's earnings, one of the primary drivers of an investment's value.Burzynski Research Systematic Risk
Burzynski Research's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Burzynski Research volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Burzynski Research correlated with the market. If Beta is less than 0 Burzynski Research generally moves in the opposite direction as compared to the market. If Burzynski Research Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Burzynski Research is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Burzynski Research is generally in the same direction as the market. If Beta > 1 Burzynski Research moves generally in the same direction as, but more than the movement of the benchmark.
Burzynski Research November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Burzynski Research help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Burzynski Research. We use our internally-developed statistical techniques to arrive at the intrinsic value of Burzynski Research based on widely used predictive technical indicators. In general, we focus on analyzing Burzynski Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Burzynski Research's daily price indicators and compare them against related drivers.
| Downside Deviation | 29.52 | |||
| Information Ratio | 0.0723 | |||
| Maximum Drawdown | 119.3 | |||
| Value At Risk | (25.45) | |||
| Potential Upside | 24.24 |
Additional Tools for Burzynski Pink Sheet Analysis
When running Burzynski Research's price analysis, check to measure Burzynski Research's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Burzynski Research is operating at the current time. Most of Burzynski Research's value examination focuses on studying past and present price action to predict the probability of Burzynski Research's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Burzynski Research's price. Additionally, you may evaluate how the addition of Burzynski Research to your portfolios can decrease your overall portfolio volatility.